RecruitingPhase 1/Phase 2

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

CRISPR Therapeutics AG · NCT07758634

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Status re-checked against ClinicalTrials.gov within the last 12 hours.

A Study of CTX340 in Participants with Uncontrolled Hypertension.

Being studied: CTX340; Placebo

Conditions: Hypertension

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

Age: ≥18 and ≤75 years.
Body mass index ≤40 kg/m2.
24-hour mean ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP) measurement of ≥130 mm Hg but ≤160 mm Hg despite treatment
Be on treatment with ≥4 antihypertensive therapies at effective doses, of which ≥1 must be a diuretic.
Participants who at any point had childbearing potential must currently be postmenopausal
All participants capable of producing sperm must agree to the use of an acceptable method of effective contraception and their partners with childbearing potential should also agree to use an effective method of contraception.

Exclusion Criteria

Serum aldosterone and direct renin concentration (or plasma renin activity [PRA]) suggestive of primary aldosteronism
Mean diastolic blood pressure (DBP) ≤65 mm Hg on screening ABPM.
Participants with vascular cause of hypertension which may be amendable to revascularization
Participants with treatable/reversible causes of uncontrolled hypertension
History of renal artery denervation within past 12 months.
Orthostatic hypotension
Complete blood count (CBC) outside the specified ranges per protocol.
Evidence of liver disease
History of a significant coagulation disorder.
Uncontrolled or untreated thyroid disease